» Articles » PMID: 25105207

Taking Aim at Alzheimer's Disease Through the Mammalian Target of Rapamycin

Overview
Journal Ann Med
Publisher Informa Healthcare
Specialty General Medicine
Date 2014 Aug 9
PMID 25105207
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

A significant portion of the world's population suffers from sporadic Alzheimer's disease (AD) with available present therapies limited to symptomatic care that does not alter disease progression. Over the next decade, advancing age of the global population will dramatically increase the incidence of AD and severely impact health care resources, necessitating novel, safe, and efficacious strategies for AD. The mammalian target of rapamycin (mTOR) and its protein complexes mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2) offer exciting and unique avenues of intervention for AD through the oversight of programmed cell death pathways of apoptosis, autophagy, and necroptosis. mTOR modulates multi-faceted signal transduction pathways that involve phosphoinositide 3-kinase (PI 3-K), protein kinase B (Akt), hamartin (tuberous sclerosis 1)/ tuberin (tuberous sclerosis 2) (TSC1/TSC2) complex, proline-rich Akt substrate 40 kDa (PRAS40), and p70 ribosomal S6 kinase (p70S6K) and can interface with the neuroprotective pathways of growth factors, sirtuins, wingless, forkhead transcription factors, and glycogen synthase kinase-3β. With the ability of mTOR to broadly impact cellular function, clinical strategies for AD that implement mTOR must achieve parallel objectives of protecting neuronal, vascular, and immune cell survival in conjunction with preserving networks that determine memory and cognitive function.

Citing Articles

The impact of aging and oxidative stress in metabolic and nervous system disorders: programmed cell death and molecular signal transduction crosstalk.

Maiese K Front Immunol. 2023; 14:1273570.

PMID: 38022638 PMC: 10663950. DOI: 10.3389/fimmu.2023.1273570.


Cornerstone Cellular Pathways for Metabolic Disorders and Diabetes Mellitus: Non-Coding RNAs, Wnt Signaling, and AMPK.

Maiese K Cells. 2023; 12(22).

PMID: 37998330 PMC: 10670256. DOI: 10.3390/cells12222595.


Malignant Brain Aging: The Formidable Link Between Dysregulated Signaling Through Mechanistic Target of Rapamycin Pathways and Alzheimer's Disease (Type 3 Diabetes).

de la Monte S J Alzheimers Dis. 2023; 95(4):1301-1337.

PMID: 37718817 PMC: 10896181. DOI: 10.3233/JAD-230555.


Innovative therapeutic strategies for cardiovascular disease.

Maiese K EXCLI J. 2023; 22:690-715.

PMID: 37593239 PMC: 10427777. DOI: 10.17179/excli2023-6306.


Cognitive Impairment in Multiple Sclerosis.

Maiese K Bioengineering (Basel). 2023; 10(7).

PMID: 37508898 PMC: 10376413. DOI: 10.3390/bioengineering10070871.


References
1.
Shahani N, Pryor W, Swarnkar S, Kholodilov N, Thinakaran G, Burke R . Rheb GTPase regulates β-secretase levels and amyloid β generation. J Biol Chem. 2013; 289(9):5799-808. PMC: 3937651. DOI: 10.1074/jbc.M113.532713. View

2.
Heitman J, Movva N, Hall M . Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991; 253(5022):905-9. DOI: 10.1126/science.1715094. View

3.
Chano T, Okabe H, Hulette C . RB1CC1 insufficiency causes neuronal atrophy through mTOR signaling alteration and involved in the pathology of Alzheimer's diseases. Brain Res. 2007; 1168:97-105. DOI: 10.1016/j.brainres.2007.06.075. View

4.
Maiese K, Chong Z, Wang S, Shang Y . Oxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascade. Int J Mol Sci. 2012; 13(11):13830-66. PMC: 3509553. DOI: 10.3390/ijms131113830. View

5.
Hou J, Wang S, Shang Y, Chong Z, Maiese K . Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress. Curr Neurovasc Res. 2011; 8(3):220-35. PMC: 3149772. DOI: 10.2174/156720211796558069. View